BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2016;34:1975-85. [PMID: 25448090 DOI: 10.1016/j.vaccine.2014.11.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Piniaeva A, Ignatyev G, Kozlovskaya L, Ivin Y, Kovpak A, Ivanov A, Shishova A, Antonova L, Khapchaev Y, Feldblium I, Ivanova O, Siniugina A, Ishmukhametov A. Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine "PoliovacSin": Clinical Trials Phase I and II. Vaccines (Basel) 2021;9:565. [PMID: 34072466 DOI: 10.3390/vaccines9060565] [Reference Citation Analysis]
2 Arita M, Iwai-Itamochi M. Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test. Sci Rep 2019;9:11970. [PMID: 31427704 DOI: 10.1038/s41598-019-48534-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kouiavskaia D, Puligedda RD, Dessain SK, Chumakov K. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines. J Virol Methods 2020;276:113785. [PMID: 31765719 DOI: 10.1016/j.jviromet.2019.113785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, Yin Q, Zhao Z, Zhang L, Lei J, Bao W, Jiang Y, Dou Y, Li J, Yang H, Cai W, Deng Y, Che Y, Shi L, Sun M. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine 2021;39:1463-71. [PMID: 33487470 DOI: 10.1016/j.vaccine.2021.01.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Nakayama T, Vidor E, Tsuzuki D, Nishina S, Sasaki T, Ishii Y, Mizukami H, Tsuge H. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. Journal of Infection and Chemotherapy 2020;26:651-9. [DOI: 10.1016/j.jiac.2019.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Satoh H, Tanaka-Taya K, Shimizu H, Goto A, Tanaka S, Nakano T, Hotta C, Okazaki T, Itamochi M, Ito M, Okamoto-Nakagawa R, Yamashita Y, Arai S, Okuno H, Morino S, Oishi K. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan. Vaccine 2019;37:1964-71. [PMID: 30827736 DOI: 10.1016/j.vaccine.2019.02.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Decker MD, Edwards KM, Howe BJ. Combination Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 198-227.e13. [DOI: 10.1016/b978-0-323-35761-6.00015-8] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, Xie S, Wen N, An Z, Chen Z, Wang H. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis 2020;20:1071-9. [PMID: 32442523 DOI: 10.1016/S1473-3099(19)30738-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
9 Viktorova EG, Khattar SK, Kouiavskaia D, Laassri M, Zagorodnyaya T, Dragunsky E, Samal S, Chumakov K, Belov GA. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. J Virol 2018;92:e00976-18. [PMID: 29925653 DOI: 10.1128/JVI.00976-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Leroux-Roels I, Leroux-Roels G, Shukarev G, Schuitemaker H, Cahill C, de Rooij R, Struijs M, van Zeeburg H, Jacquet JM. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults. Hum Vaccin Immunother 2021;17:1366-73. [PMID: 33175637 DOI: 10.1080/21645515.2020.1812315] [Reference Citation Analysis]
11 Murakami K, Fujii Y, Someya Y. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats. Vaccine 2020;38:3295-9. [PMID: 32197923 DOI: 10.1016/j.vaccine.2020.03.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fox H, Knowlson S, Minor PD, Macadam AJ. Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines. PLoS Pathog 2017;13:e1006117. [PMID: 28103317 DOI: 10.1371/journal.ppat.1006117] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
13 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Hotta C, Ogawa T, Shirasawa H. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Hum Vaccin Immunother 2019;15:1154-9. [PMID: 30676843 DOI: 10.1080/21645515.2019.1572408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Someya Y, Ami Y, Takai-Todaka R, Fujimoto A, Haga K, Murakami K, Fujii Y, Shirato H, Oka T, Shimoike T, Katayama K, Wakita T. Evaluation of the use of various rat strains for immunogenic potency tests of Sabin-derived inactivated polio vaccines. Biologicals 2018;52:12-7. [PMID: 29475730 DOI: 10.1016/j.biologicals.2018.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Chong PF, Kira R, Mori H, Okumura A, Torisu H, Yasumoto S, Shimizu H, Fujimoto T, Hanaoka N, Kusunoki S, Takahashi T, Oishi K, Tanaka-Taya K; Acute Flaccid Myelitis Collaborative Study Investigators. Clinical Features of Acute Flaccid Myelitis Temporally Associated With an Enterovirus D68 Outbreak: Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August-December 2015. Clin Infect Dis 2018;66:653-64. [PMID: 29028962 DOI: 10.1093/cid/cix860] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 31.5] [Reference Citation Analysis]
17 Shi L, Sun M. The progress of postapproval clinical studies on Sabin IPV. Hum Vaccin Immunother 2021;:1-4. [PMID: 34213408 DOI: 10.1080/21645515.2021.1940653] [Reference Citation Analysis]
18 Tanaka Y, Yokokawa R, Rong HS, Kishino H, Stek JE, Nelson M, Lawrence J. Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants. Hum Vaccin Immunother 2017;13:1-7. [PMID: 28140752 DOI: 10.1080/21645515.2017.1279769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Shin WJ, Hara D, Gbormittah F, Chang H, Chang BS, Jung JU. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine. mBio 2018;9:e02287-18. [PMID: 30482835 DOI: 10.1128/mBio.02287-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
20 Kang G, Tang F, Wang Z, Hu R, Yu J, Gao J. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China. Hum Vaccin Immunother 2021;17:2568-74. [PMID: 33780310 DOI: 10.1080/21645515.2021.1898306] [Reference Citation Analysis]
21 Zaman K, Anand A. Complex task to estimate immune responses to various poliovirus vaccines and vaccination schedules. The Lancet Infectious Diseases 2019;19:1043-5. [DOI: 10.1016/s1473-3099(19)30322-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Fan S, Liao Y, Lian Y, Jiang G, Jiang L, Dong C, Yang E, Wang L, Xu X, Feng M, Zhang Y, Li Q. Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen. NPJ Vaccines 2019;4:14. [PMID: 30937186 DOI: 10.1038/s41541-019-0108-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]